Positron Emission Tomography/Computed Tomography (PET/CT)-Based, Local Consolidative Radiotherapy after Chemoimmunotherapy in Metastatic, Non-Oncogene-Addicted Non-Small-Cell Lung Cancer (NSCLC)-Reference-Cited by-同舟云学术

Positron Emission Tomography/Computed Tomography (PET/CT)-Based, Local Consolidative Radiotherapy after Chemoimmunotherapy in Metastatic, Non-Oncogene-Addicted Non-Small-Cell Lung Cancer (NSCLC)

Published:2023-04-25 Issue:9 Volume:13 Page:1538
ISSN:2075-4418
Container-title:Diagnostics
language:en
Short-container-title:Diagnostics

Author:

Angelini Lucia¹²^ORCID,Pazos Montserrat²,Käsmann Lukas²³⁴,Manapov Farkhad²³⁴

Affiliation:

1. Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy

2. Department of Radiation Oncology, University Hospital, LMU Munich, Ziemsenstrasse 1, 80336 Munich, Germany

3. German Center for Lung Research (DZL), Comprehensive Pneumology Center Munich (CPC-M), 81377 Munich, Germany

4. German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany

Abstract

The optimal sequence of chemo/immuno- and radiotherapy (RT) in metastatic non-small-cell lung cancer (NSCLC) remains challenging. Here, we describe the case of a 58-year-old female patient with an initially metastasized NSCLC obtaining local and distance durable response after chemo-immunotherapy and local RT associated with immunotherapy maintenance. Our experience offers a valuable perspective in choosing how to combine therapies to ensure the longest possible response in patients with estimated poor prognosis.

Publisher

MDPI AG

Subject

Clinical Biochemistry

Link

https://www.mdpi.com/2075-4418/13/9/1538/pdf

Reference19 articles.

1. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial;West;Lancet Oncol.,2019

2. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors;Wahl;J. Nucl. Med.,2009

3. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial;Shaverdian;Lancet Oncol.,2017

4. Santos, P.M.G., Li, X., and Gomez, D.R. (2022). Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer. Cancers, 14.

5. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study;Gomez;Lancet Oncol.,2016